Journal of Clinical and Cellular Immunology
Open Access

Paul David

Publications

• Research Article
  Sequential Therapy with Tenofovir Plus Peg Interferon Enhances Innate and Adaptive Immunity Compared to Tenofovir Monotherapy in Chronic Hepatitis B Patients
  Author(s): Nirupma Trehanpati, Arshi Khanam, Syed Hissar, Rashi Sehgal, Ritu Khosla, Paul David, Ashish kumar, Anupama Prashar, Ankit Bhardwaj, Shyam Kottilil and Shiv Kumar SarinNirupma Trehanpati, Arshi Khanam, Syed Hissar, Rashi Sehgal, Ritu Khosla, Paul David, Ashish kumar, Anupama Prashar, Ankit Bhardwaj, Shyam Kottilil and Shiv Kumar Sarin
  
  Viral load reduction followed by immunomodulation is an emerging approach to improve the treatment outcomes in patients with Chronic Hepatitis B (CHB). Persistent functional defects in Dendritic Cells (DC) have been observed in CHB patients, even with effective antiviral therapy. We investigated the effects of Tenofovir plus Peg-IFN Sequential Therapy (SQT) on functional restoration of innate and adaptive immunity in CHB patients. HBeAg+ve CHB patients were randomized to receive 48weeks of either tenofovir monotherapy (TM; Gr.1, n=30) or tenofovir with addition of PEG interferon from week 12 to 36 followed by tenofovir sequential therapy (SQT; Gr. 2, n=28) for 48 weeks. Biochemical parameters improved significantly with treatment at week 24 in both groups, but HBeAg seroconversion at week 48 occurred more frequently after SQT (21%) than TM (13%). At week 2.. View More»
  DOI: 10.4172/2155-9899.1000272

  Abstract PDF

Relevant Topics